

Priority Data (CC No Date) : CN 91104811 (910718)
Applications (CC, No, Date) : US 912791 (920713)

18879922 WPI Acc No: 92-007193/01
CAN Acc No: C92-003067
Treatment of poly-drug* dependency* - with bogaine*, libogaine or
tabernanthine or their salts or deriv.; *ALKALOID*
Patent Assignee: (NDAT-) NDA INT INC; (LOTS-) LOTSOF H S
Author (Inventor): LOTSOF H S
Current Family: LOTSOF H S
CC Number: Kind Date
Week

riority Data (CC No Date): US 531100 (900531)
Applications (CC, No, Date): EP 911910992 (910530); WO 91US3781 (910530)

1/3/30 (Item 3 from file: 351)
(ANALOG (R) File 351: DERWENT WPI
) 1994 Derwent Info Ltd. All rts.

14808190 WPI Acc No: 86-311531/47
Related WPI Accession(s): 83-27318K
PAM Acc No: C86-134925
Preventing *dependence* on psycho-active *drugs* e.g. narcotics by
admin. of hapten conjugate of drug with macromolecule, e.g. serum
albumin; HAPTFEN
Assignee: (STRA/)
Inventor (Inventor): STRAHLLEVITZ M

Acct. Num. 4620977
CC No 319238
Date 8/11/09
Priority Basic
US 7116001
US 710520

5/3/31 (Item 4 from file: 351)
CATALOG (R) File 351: DERWENT WPT
c) 1994 Derwent Info Ltd. All rts.

03850067 WPT Acc No: 83-846318/51
RAM Acc No: C83-123508
Dynorphin amide analogues useful for potentiating narcotic and peptide
analgesics and *treating* narcotic* withdrawal*
Agent Assignee: (REGC) UNIV OF CALIFORNIA (REGC) UNIV CALIFORNIA
Author (Inventor): LEE N M; LOH H H; CHANG J K

CC Number	Kind	Date	Week	(Basic)
EP 96592	A	831221	8351	
AU 83144389	A	831215	8406	
NO 8302107	A	840102	8408	
FI 8302095	A	840131	8411	
DK 8302626	A	840130	8411	
JP 59025365	A	840209	8412	
ZA 8304189	A	840118	8413	
HU T30731	T	840328	8420	
PT 76860	A	840529	8427	
US 4462941	A	840731	8433	
US 4462941	A	840731	8433	
US 4462941	A	840731	8433	

BEST AVAILABLE COPY

Language: English

/3/24 (Item 24 from file: 144)
ALOG(R)File 144:Pascal
) 1994 INIST/CNRS. All rts. reserv.

08743484 PASCAL No.: 89-0292766
Effect of *ibogaine* on haloxone-precipitated withdrawal syndrome in
chronic morphine-dependent rats
DZOLJIC E D; KAPLAN C D; DZOLJIC M R
Erasmus univ., medical fac., dep. pharmacology, Rotterdam DR 3000,
therlands
Journal: Archives internationales de Pharmacodynamie et de Therapie,
88, 294 64-70
Language: English

/3/25 (Item 25 from file: 144)
ALOG(R)File 144:Pascal
) 1994 INIST/CNRS. All rts. reserv.

03614493 PASCAL No.: 82-0128557
TOLFENAMIC ACID AND ERGOTAMINE ABUSE
ALA-HURULA V; MULLYLA V V; HOKKANEN E; TOKOLA O
UNIV. CENT. HOSP. OULU/OLU, FINLAND
Journal: HEADACHE, 1981, 21 (6) 240-242
Language: ENGLISH

/3/26 (Item 26 from file: 144)
ALOG(R)File 144:Pascal
) 1994 INIST/CNRS. All rts. reserv.

02062457 PASCAL No.: 78-0409456
PEYOTL, A POTENTIAL ETHNOPHARMACOLOGIC AGENT FOR *ALCOHOLISM* AND OTHER
DRUG* *DEPENDENCIES*: POSSIBLE BIOCHEMICAL RATIONALE.
BLUM K; FUTTERMAN S L; PASCAROSA P
UNIV. TEXAS HEALTH SCI. CENT.; SAN ANTONIO, TEX. 78284
Journal: CLIN. TOXICOLOGY, 1977, 11 (4) 459-472
Language: ENGLISH

/3/27 (Item 1 from file: 350)
ALOG(R)File 350:Derwent World Pat.
) 1994 Derwent Info Ltd. All rts. reserv.

1376057 WPI Acc No: 75-25708W/15
AM Acc No: C75-W25708
Glucose-6-phosphate dehydrogenase conjugated drugs - useful for enzyme
immunoassays
Assignee: (SYNT) SYVA CO
Item Family:
CC Number Kind Date Week
US 3875011 A 750401 7515 (Basic)
Priority Data (CC No Date): US 438690 (740201); US 143609 (710514); US
304157 (721106)

/3/28 (Item 1 from file: 351)
ALOG(R)File 351:Derwent WPI
) 1994 Derwent Info Ltd. All rts. reserv.

19794530 WPI Acc No: 94-074383/09
AM Acc No: C94-033856
Treatment of *narcotic* withdrawal symptoms - with Acconitum

BEST AVAILABLE COPY

11360314 PASCAL No.: 94-0183191
Effects of the calcium antagonist isradipine on cocaine intravenous self-administration in rats
MARTELLORTA M C; KUZMIN A; MUGLIA P; GESSA G L; FRATTA W
Univ. Cagliari, B.B. Brodile dep. neurosci., 09124 Cagliari, Italy
Journal: Psychopharmacology, 1994, 113 (3-4) 378-380
Language: English

5/3/11 (Item 11 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11307982 PASCAL No.: 94-0128604
Persistence of the ability of amphetamine preexposure to facilitate acquisition of cocaine self-administration
VALADEZ A; SCHENK S
Texas A&M univ., dep. psychology, College Station TX 77843, USA
Journal: Pharmacology, biochemistry and behavior, 1994, 47 (1) 203-205
Language: English

5/3/12 (Item 12 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11307958 PASCAL No.: 94-0128580
Ibogaine reduces preference for cocaine consumption in C57BL/6By mice
SERSHEN H; HASHIM A; LAJTHA A
Cent. neurochemistry, N.S. Kline inst., Orangeburg NY 10962-2210, USA
Journal: Pharmacology, biochemistry and behavior, 1994, 47 (1) 13-19
Language: English

5/3/13 (Item 13 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11236289 PASCAL No.: 94-0054203
Comparison of the behavioral effects of *ibogaine* from three sources: mediation of discriminative activity
SCHECHTER M D; GORDON T L
Northeast Ohio univ. coll. medicine dep. pharmacology, Rootstown OH 44272-0095, USA
Journal: European journal of pharmacology, 1993, 249 (1) 79-84
Language: English

5/3/14 (Item 14 from file: 144)
DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11184773 PASCAL No.: 94-0001555
Cocaine administration prior to reactivation facilitates later acquisition of an avoidance response in rats
RODRIGUEZ W A; PHILLIPS N Y; RODRIGUEZ S B; MARTINEZ J I, JR
Univ. California, dep. psychology, Berkeley CA 94720, USA
Journal: Psychopharmacology, 1993, 112 (2-3) 366-370
Language: English

11541249 PASCAL No.: 94-0421753

Gastric antiulcer and cytoprotective effects of cathinone, a psychoactive alkaloid, of Khat (Catha edulis Forsk.) and amphetamine in rats
Towards a molecular basis in opioid research
AL-SHABANAH O. A.; AL-GHARABLY N M; ISLAM M W; AL-HARBI N M
NYBERG Fred, ed; POST Claes, ed; VAN REE Jan, ed; SCHULZ Rudiger, ed;
TERENTIUS Lars, ed
King Saud univ., coll. pharmacy, dep. pharmacology, Riyadh 11451, Saudi
Arabia

Uppsala univ., dep. pharmaceutical biosci., 751 85 Uppsala, Sweden
INRC : international narcotics research conference, 24 (Skoevde SWE)
1993-07-10
Journal: Regulatory peptides, 1994 (SUP1) S297-S299
Language: English

5/3/4 (Item 4 from file: 144)

DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11524211 PASCAL No.: 94-0367001
Open-label, dose run-up study of diethylpropion in initial cocaine
abstinence

ALIM T N; ROSSE R B; VOCCI F J JR; DEUTSCH S I
Dep. veterans affairs medical cent., psychiatry serv., VA/NIDA res. unit,
Washington DC 20422, USA
Journal: Clinical neuropharmacology, 1994, 17 (2) 175-187
Language: English

5/3/5 (Item 5 from file: 144)

DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11509807 PASCAL No.: 94-0350529

Lisuride reduces intravenous cocaine self-administration in rats
PULVIRENTI L; KOOB G F
Scripps res. inst., dep. neuropharmacology, La Jolla CA 92037, USA
Journal: Pharmacology, biochemistry and behavior, 1994, 47 (4) 819-822
Language: English

5/3/6 (Item 6 from file: 144)

DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11486405 PASCAL No.: 94-0324399

The 5-HT₂ SUB 3 antagonist zacopride attenuates cocaine-induced increases
in extracellular dopamine in rat nucleus accumbens
MCNEISH C S; SWINGOS A L; HIRZEMANN R; STRECKER R E
State univ. New York Stony Brook, dep. psychiatry behavioral sci., Stony
Brook NY 11794-8790, USA
Journal: Pharmacology, biochemistry and behavior, 1993, 45 (4) 759-763
Language: English

5/3/7 (Item 7 from file: 144)

DIALOG(R)File 144:Pascal
(c) 1994 INIST/CNRS. All rts. reserv.

11424023 PASCAL No.: 94-0257623

Selective antagonism of dopamine D₁ and D₂ receptors does not
block the development of behavioral sensitization to cocaine
MATTINGLY B A; HART T C; LIM K; PERKINS C
Morehead State univ., dep. psychology, Morehead KY 40351-1689, USA

BEST AVAILABLE COPY

EP 449247 A 911002 91140 (Basic)
 DE 4010079 A 911002 9141
 CA 2039197 A 910930 9151
 DE 4010079 C 920730 9231
 JP 4221315 A 920811 9238
 EP 449247 A3 920304 9325
 EP 449247 B1 940720 9428
 Priority Data (CC No Date): DE 4010079 (900329)
 Applications (CC, No, Date): EP 91104858 (910327); DE 4010079 (900329); JP 9164275 (910328); EP 91104858 (910327); EP 91104858 (910327)
 Abstract (Basic): EP 449247 A

Galanthamine (I) or its acid-addn. salts are used to prepare medicaments for *treating* alcoholism.

(I) is a snowdrop *alkaloid*, e.g. described in J. Gen. Chem., 22, 1899 (1952), namely 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef) (2) benzazepin-6-ol of formula (I).

(I) is a reversible cholinesterase inhibitor with a similar action to physostigmine and neostigmine, but with lower toxicity. At doses of 5 and 10 mg/kg (p.o.), it reduces alcohol consumption in ethanol-prefering rats from 6.47 and 6.30 g/kg respectively to 3.17 and 3.71 g/kg respectively, without significant affecting food and drink intake.

(I) may be formulated for transdermal, oral or parenteral admin., opt. in slow-release form. Dosages are not specified. @ (7pp Dwg. No. 0/0

Abstract (EP): 9428 EP 4-3247 B

The use of a *pharmaceutic* formulation containing galanthamine or one of the *pharmaceutically* acceptable acid addition salts thereof for the manufacture of a *pharmaceutic* product for reducing the compulsive desire (*craving*) for *alcohol* in the *treatment* of chronic alcoholism. Dwg. 0/0
 Abstract (DE): 9231 DE 4010079 C
 Galanthamine or 3-methoxy-6-hydroxy-11-methyl-4a,5,9,10,11,12-hexahydro-benzofuro (3a,3,2-ef) (2) benzazepine of formula (I) or its non-toxic salt is used for the *treatment* of alcoholism. Active substance is dispersed with the usual carriers and opt. additives, and is administered orally, transdermally or parenterally.
 Dwg. 0/0

4/3, AB/8 (Item 5 from file: 351)
 DIALOG (R) File 351:DERWENT WPI
 (c) 1994 Derwent Info Ltd. All rts. reserv. .

008035267 WPI Acc No: 89-300379/41
 XRAM Acc No: C89-132881
 XRPX Acc No: N89-229131

Alcohol *dependency* and *abuse* *treatment* - comprises
 administering *ibogaine* and/or its non-toxic salts
 Patent Assignee: (NDAT-) NDA INT INC
 Author (Inventor): LOTSOF H S
 Patent Family:
 CC Number Kind Date Week

US 4857523 A 890815 8941 (Basic)
 Priority Data (CC No Date): US 221030 (880718)
 Abstract (Basic): US 4857523

Treating *alcohol* *dependency* and *abuse* comprises internally administering a dosage of 4-25 mg/kg of *ibogaine* and/or its *therapeutically* active cpd.
 The dosage is administered orally and the *compsn* contains *ibogaine* and/or its hydro chloride or hydrobromide in a dosage of 400-1000 mg. The dosage is pref. in capsule, tablet, pill, powder or soln. form and is admixed with binders or fillers. A plurality of dosages are administered, intervals of a number of days intervening between successive dosages. A single *treatment* is effective for about

BEST AVAILABLE COPY